(Q87412311)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

main subject

phase I clinical trial

1 reference

Quincy S Chu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Randeep Sangha

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Sebastien J Hotte

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Gwen Sergenson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

David Schnell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Vikram K Chand

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Hal W Hirte

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

19 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

1226-1235

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours

9 March 2020

cites work

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

1 reference

12 December 2020

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

12 December 2020

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

1 reference

12 December 2020

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

12 December 2020

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

1 reference

12 December 2020

Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial

1 reference

12 December 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

12 December 2020

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

12 December 2020

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent

1 reference

12 December 2020

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

12 December 2020

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

12 December 2020

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

12 December 2020

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors

1 reference

12 December 2020

Mechanisms of resistance to EGFR targeted therapies

1 reference

12 December 2020

Diarrhea associated with afatinib: an oral ErbB family blocker

1 reference

12 December 2020

Dose reduction or intermittent administration of erlotinib: which is better for patients suffering from intolerable toxicities?

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

12 December 2020

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

1 reference

12 December 2020

Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor

1 reference

12 December 2020

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

12 December 2020

Pemetrexed for the treatment of non-small cell lung cancer.

1 reference

12 December 2020

10.1007/S10637-014-0139-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037863%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference